financetom
Business
financetom
/
Business
/
Euro Manganese Raising Funds to Advance Chvaletice Project in Czech Republic
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Euro Manganese Raising Funds to Advance Chvaletice Project in Czech Republic
Mar 6, 2025 5:55 AM

08:37 AM EST, 03/06/2025 (MT Newswires) -- Euro Manganese ( EUMNF ) said on Thursday that it is raising $5.9 million in a conditional placement of common shares and CHESS Depositary Interests (CDI) to advance the Chvaletice manganese project in the Czech Republic.

The funds will be used to engage with customers to secure additional offtake term sheets and strategic investments.

"This critical financing enables the Company to pursue certain key milestones and advance project development, including securing offtake agreements and additional offtake term sheets, and pursuing an investment from a strategic investor, the operation of the demonstration plant to market our product to potential customers and to advance permitting," said Martina Blahova, the interim CEO.

The offering is priced at $0.036 pre-consolidation per new security, including a subscription from the European Bank for Reconstruction and Development of about $3.1 million. This will result in the bank increasing its pro forma ownership in the Company to 19.99%.

Under the equity raising, investors will receive one warrant to purchase an additional common share or CDI for every one new security subscribed for, with an exercise price of $0.045 per warrant and an expiry date 18 months.

In addition to the conditional placement, Euro Manganese ( EUMNF ) said it intends to offer eligible existing shareholders the opportunity to participate in a share purchase plan to raise up to a further $3.6 million at the equity raising price.

Meanwhile, Euro Manganese ( EUMNF ) appointed Rick Anthon as chairman of the board of directors.

John Webster, who has served as chairman since 2020, will remain in the role until Anthon's formal appointment following completion of the conditional placement. Webster will continue as non-executive director after Anthon's appointment.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Adidas sees $140 million hit on operating profit from US tariffs
Adidas sees $140 million hit on operating profit from US tariffs
Oct 29, 2025
(Reuters) -Adidas expects U.S. import tariffs to have a direct impact of 120 million euros ($140 million) on its operating profit in 2025, with the largest hit coming in the fourth quarter, its CEO said on Wednesday. The indirect impact of the tariffs, we don't know. We do not know how the consumer will react in the U.S. when these...
Form 8.3 - Spectris PLC
Form 8.3 - Spectris PLC
Oct 29, 2025
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of...
Market Chatter: Thermo Fisher Nearing $10 Billion Takeover of Clario
Market Chatter: Thermo Fisher Nearing $10 Billion Takeover of Clario
Oct 29, 2025
06:06 AM EDT, 10/29/2025 (MT Newswires) -- Thermo Fisher Scientific ( TMO ) is close to acquiring drug trial software maker Clario in an all-cash deal that could value the healthcare technology group at about $10 billion, the Financial Times reported Tuesday, citing people familiar with the matter. A deal could be announced as early as Wednesday, two sources told...
BRIEF-Nls Pharmaceutics Announces 1-for-10 Reverse Share Split And Name Change In Connection With Proposed Merger With Kadimastem
BRIEF-Nls Pharmaceutics Announces 1-for-10 Reverse Share Split And Name Change In Connection With Proposed Merger With Kadimastem
Oct 29, 2025
Oct 29 (Reuters) - NLS Pharmaceutics AG ( NLSP ): * NLS PHARMACEUTICS LTD. ANNOUNCES 1-FOR-10 REVERSE SHARE SPLIT AND NAME CHANGE IN CONNECTION WITH PROPOSED MERGER WITH KADIMASTEM * NLS PHARMACEUTICS ( NLSP ) - REVERSE SPLIT EFFECTIVE IN SWITZERLAND ON OCTOBER 30, 2025 * NLS PHARMACEUTICS ( NLSP ) - COMMON SHARES TO TRADE ON NASDAQ AS NCEL...
Copyright 2023-2026 - www.financetom.com All Rights Reserved